Your browser is no longer supported. Please, upgrade your browser.
Iovance Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own0.64% Shs Outstand138.30M Perf Week-0.17%
Market Cap4.59B Forward P/E- EPS next Y-1.89 Insider Trans0.00% Shs Float135.58M Perf Month-9.16%
Income-259.60M PEG- EPS next Q-0.48 Inst Own- Short Float15.72% Perf Quarter-42.07%
Sales- P/S- EPS this Y-18.10% Inst Trans5.31% Short Ratio11.74 Perf Half Y-12.89%
Book/sh4.75 P/B6.35 EPS next Y7.40% ROA-39.10% Target Price52.00 Perf Year-14.38%
Cash/sh4.13 P/C7.30 EPS next 5Y- ROE-43.80% 52W Range24.67 - 54.21 Perf YTD-35.04%
Dividend- P/FCF- EPS past 5Y-24.70% ROI- 52W High-44.40% Beta0.81
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low22.17% ATR2.08
Employees241 Current Ratio11.60 Sales Q/Q- Oper. Margin- RSI (14)40.50 Volatility6.17% 6.38%
OptionableYes Debt/Eq0.00 EPS Q/Q1.70% Profit Margin- Rel Volume1.16 Prev Close30.43
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume1.82M Price30.14
Recom1.70 SMA20-1.84% SMA50-18.01% SMA200-18.19% Volume2,099,956 Change-0.95%
Apr-16-21Initiated Goldman Buy $97
Mar-08-21Upgrade H.C. Wainwright Neutral → Buy $50
Dec-15-20Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20Initiated Mizuho Buy $61
Mar-04-20Initiated Barclays Overweight $45
Feb-26-20Reiterated Oppenheimer Outperform $32 → $35
Feb-26-20Reiterated H.C. Wainwright Buy $32 → $36
Dec-18-19Initiated JMP Securities Mkt Outperform $38
Oct-01-19Initiated Stifel Buy $27
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $24
Jul-06-18Reiterated Chardan Capital Markets Buy
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Apr-12-21 12:43PM  
Apr-09-21 07:00AM  
Apr-01-21 06:27AM  
Mar-30-21 02:55PM  
Mar-27-21 11:31AM  
Mar-22-21 11:11AM  
Mar-15-21 04:01PM  
Mar-10-21 05:28PM  
Mar-07-21 03:42AM  
Mar-01-21 04:01PM  
Feb-26-21 10:13AM  
Feb-25-21 04:01PM  
Feb-18-21 07:30AM  
Jan-19-21 08:56AM  
Dec-28-20 07:30AM  
Dec-15-20 02:24PM  
Dec-14-20 07:00AM  
Dec-05-20 11:32AM  
Nov-30-20 07:21AM  
Nov-09-20 08:58AM  
Nov-05-20 04:00PM  
Oct-30-20 07:00AM  
Oct-29-20 11:11AM  
Oct-28-20 07:45AM  
Oct-14-20 05:01PM  
Oct-09-20 10:12PM  
Oct-08-20 05:48PM  
Oct-07-20 10:49AM  
Oct-06-20 09:43AM  
Oct-05-20 04:01PM  
Sep-07-20 03:46PM  
Sep-05-20 11:32AM  
Aug-10-20 11:22AM  
Aug-07-20 07:30AM  
Aug-06-20 04:01PM  
Aug-04-20 05:33PM  
Jul-23-20 07:30AM  
Jul-15-20 01:15PM  
Jul-14-20 12:49PM  
Jul-01-20 07:11AM  
Jun-08-20 04:01PM  
Jun-04-20 11:31AM  
Jun-02-20 04:01PM  
Jun-01-20 09:20AM  
May-29-20 08:01AM  
May-28-20 09:30PM  
May-27-20 04:20PM  
May-13-20 05:01PM  
May-11-20 11:13PM  
May-08-20 11:46AM  
May-06-20 11:26AM  
May-05-20 04:01PM  
Apr-30-20 06:13PM  
Apr-29-20 12:01PM  
Apr-27-20 04:01PM  
Apr-17-20 08:43AM  
Apr-16-20 04:11PM  
Apr-13-20 05:14PM  
Mar-27-20 02:55PM  
Mar-11-20 09:18AM  
Mar-10-20 08:23AM  
Mar-02-20 04:01PM  
Feb-25-20 05:46PM  
Feb-19-20 07:00AM  
Feb-12-20 07:00AM  
Jan-15-20 08:00AM  
Jan-13-20 04:15PM  
Jan-12-20 04:30PM  
Dec-26-19 11:25AM  
Dec-23-19 05:40AM  
Dec-16-19 03:55PM  
Dec-04-19 08:03PM  
Dec-02-19 07:00AM  
Nov-21-19 07:00AM  
Nov-08-19 02:58PM  
Nov-07-19 04:32PM  
Nov-04-19 04:01PM  
Oct-31-19 04:43PM  
Oct-21-19 10:55AM  
Oct-02-19 07:00AM  
Oct-01-19 01:48PM  
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universite de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.